Patents by Inventor Michael Vachon

Michael Vachon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200030758
    Abstract: An extendable auger having a base section, an extension section, an extension fixation assembly and a cover. The base section includes a base section central shaft having a hollow core and a base section helical member. The extension section is positionable over the base section and includes an extension section central shaft having a hollow core and an extension section helical member. The extension fixation assembly includes a base support wall positioned at the top end of the base section central shaft and an extension abutment wall positioned at the bottom end of the extension section central shaft. The base support wall is superposable to the extension abutment wall and securable thereagainst. The extension fixation assembly further includes a fastening assembly configured to removably secure the extension section to the base section, when the base support wall and the extension abutment wall are superposed to one another.
    Type: Application
    Filed: July 30, 2018
    Publication date: January 30, 2020
    Applicant: Groupe Anderson Inc.
    Inventors: Patrice Desrochers, Jordan Vachon, Jacques Breton, Michaƫl Gagnon-Bouchard
  • Publication number: 20160228378
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Application
    Filed: December 23, 2015
    Publication date: August 11, 2016
    Applicant: Edgemont Pharmaceuticals, LLC
    Inventors: Douglas A. Saltel, Michael Vachon
  • Publication number: 20150190345
    Abstract: Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 9, 2015
    Inventors: Douglas A. Saltel, Michael Vachon
  • Publication number: 20150174078
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Application
    Filed: March 4, 2015
    Publication date: June 25, 2015
    Applicant: EDGEMONT PHARMACEUTICALS
    Inventors: Douglas A. Saltel, Michael Vachon
  • Publication number: 20150110874
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Application
    Filed: January 8, 2014
    Publication date: April 23, 2015
    Inventors: Douglas A. Saltel, Michael Vachon
  • Patent number: 8999393
    Abstract: A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: April 7, 2015
    Assignee: Edgemont Pharmaceuticals LLC
    Inventors: Douglas A. Saltel, Michael Vachon
  • Publication number: 20140187842
    Abstract: Device for the neutralization and disposal of unused human or animal pharmaceutical medicament. The device comprises a disposal device material that contains one or more disposal device agents. The disposal device material may also contain additional components to promote mixing, or neutralization of the active agent of the medicament. The disposal device material can be in the form of pellets, beads, beadlets, granules, or the like, and can be incorporated into a disposal device reservoir. The disposal device can be dispensed with a medicament, and the device can be used when the patient has finished using the medicament and there is material left over for disposal.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: QRxPharma Ltd.
    Inventors: John W. Holaday, Edward M. Rudnic, Beth A. Burnside, Marcus Schestopol, Donald Treacy, Michael Vachon, Sean Higgins, Gary W. Pace
  • Patent number: 8703202
    Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: April 22, 2014
    Assignee: Jagotec AG
    Inventors: Michael Vachon, Mishra K. Awadhesh, Robert A. Snow, Pol-Henri Guivarc'h
  • Patent number: 8586094
    Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: November 19, 2013
    Assignee: Jagotec AG
    Inventors: Michael Vachon, Mishra K. Awadesh, Robert A. Snow, Pol-Henri Guivarc'H
  • Publication number: 20130022646
    Abstract: Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
    Type: Application
    Filed: April 9, 2012
    Publication date: January 24, 2013
    Inventors: Edward M. Rudnic, Michael Vachon, Gary W. Pace
  • Publication number: 20120321716
    Abstract: Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 20, 2012
    Inventors: Michael VACHON, Edward M. RUDNIC
  • Publication number: 20120321674
    Abstract: Abuse resistant pharmaceutical formulations are provided that contain one or more abusable drugs and one or more abuse deterrent components. The abuse deterrent component(s) prevent the abusable drug(s) from being removed/extracted to an appreciable extent and/or rate. The abuse deterrent component(s) may be in the form of pellets, beads, beadlets, granules, powders, or the like, and may comprise a core that contains a material that is both hydrophilic and hydrophobic, and optionally a pH-dependent coating.
    Type: Application
    Filed: February 18, 2012
    Publication date: December 20, 2012
    Inventors: Michael Vachon, Edward M. RUDNIC
  • Publication number: 20110195989
    Abstract: Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
    Type: Application
    Filed: February 9, 2011
    Publication date: August 11, 2011
    Inventors: Edward M. Rudnic, Michael Vachon, Gary W. Pace, Joseph Berry, Felix de la Iglesia
  • Publication number: 20060257494
    Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
    Type: Application
    Filed: July 24, 2006
    Publication date: November 16, 2006
    Inventors: Michael Vachon, Awadhesh Mishra, Robert Snow, Pol-Henri Guivarc'h
  • Publication number: 20040091535
    Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.
    Type: Application
    Filed: May 2, 2003
    Publication date: May 13, 2004
    Applicant: SKYEPHARMA CANADA INC.
    Inventors: Michael Vachon, Awadhesh K. Mishra, Robert A. Snow, Pol-Henri Guivarc'H